Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 14, 2019, covering events occurring between May 21, 2019, and June 11, 2019. The company is an emerging growth company incorporated in Delaware and trades on the NASDAQ Capital Market.
Key Financial Metrics and Transactions
The filing details unregistered sales of equity securities involving the conversion of debt to equity. Between May 21 and June 11, 2019, the company issued a total of 349,275 shares of Common Stock to a noteholder in exchange for reductions in the outstanding balance of a secured promissory note. The aggregate debt reduction totaled $2,769,175.
| Date | Shares Issued | Debt Reduction Amount |
|---|---|---|
| May 29, 2019 | 25,210 | $300,000 |
| June 3, 2019 | 21,632 | $250,000 |
| June 10, 2019 | 78,683 | $550,000 |
| June 11, 2019 | 223,750 | $1,669,175 |
| Total | 349,275 | $2,769,175 |
The filing states that these issuances resulted in the issuance of more than 5% of the Company's issued and outstanding shares of common stock as last reported in the Form 10-Q filed on May 21, 2019. The filing text does not provide specific values for revenue, profit, cash flow, margins, or total liquidity positions.
Material Changes and Unusual Items
The primary material change is the significant dilution of existing shareholders due to the issuance of over 5% of the company's outstanding common stock to settle debt obligations. This transaction was executed under Section 3(a)(9) of the Securities Act, which provides an exemption from registration for exchanges of securities with existing security holders.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary is qualified by reference to the full Exchange Agreement. The company expects to file the form of the Exchange Agreement as an exhibit to its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019.
Key Facts for Investor Verification
- Verify the exact percentage of total outstanding shares represented by the 349,275 newly issued shares to assess dilution impact.
- Confirm the remaining balance of the secured promissory note following the $2.77 million reduction.
- Review the full Exchange Agreement (to be filed in the Q2 2019 10-Q) for any covenants, warrants, or future conversion rights attached to the transaction.
- Check the May 21, 2019 Form 10-Q to establish the baseline share count prior to these transactions.